Good morning, and welcome to Marinus Pharmaceuticals 2021 Annual Meeting of Stockholders. I am Scott Braunstein, Chief Executive Officer and a director of Marinus, and I will be presiding over this meeting. It is now 9:30 A.M. I call the meeting to order. We are also joined by Steven Pfanstiel, our Chief Financial Officer, Martha Manning, our Vice President, General Counsel, and Corporate Secretary, and Sasha Demetriou, Vice President, Investor and Corporate Communications. In addition, we have with us today from our board of directors, Nicole Vitullo, Chairperson of the Board, Charles Austin, Michael Dougherty, Elan Ezickson, Seth H. Z. Fischer, and Saraswathy Nochur. From Ernst & Young LLP, Marinus' independent registered public accounting firm, we have Ryan Carrozza, who is available to respond to questions. Ms. Manning will serve as secretary of the meeting as well as the Inspector of Elections. Ms. Manning previously took her oath to serve as Inspector of Elections. A copy of Ms. Manning's oath will be made as part of the minutes of this meeting. The formal portion of this meeting will consist of two parts. First, the formalities necessary to establish the validity of the meeting, and second, the meeting's formal business, which is to act on three proposals. If a stockholder has a question about one of the proposals to be voted on, such question may be submitted by clicking the Q&A button on the bottom right of the web portal before the time the matters are before the annual meeting for consideration. You must be logged into the meeting using our control number in order to submit a question. Because we have not received advance notice from any of our stockholders on any other matters to be considered at today's meeting, as required under the rules of the Securities and Exchange Commission and by our bylaws, no other proposals may be properly introduced by stockholders. Following the conclusion of the formal portion of this meeting, we will hold a question and answer session. I now ask that Ms. Manning report on the existence of a quorum. As noted in the notice of annual meeting made available to all stockholders, the record date for this meeting was the close of business on March 30, 2021. I have an affidavit from Broadridge Financial Solutions to the effect that it has mailed on behalf of Marinus to each stockholder of record on March 30, 2021, a copy of the notice of Internet availability of proxy materials, and if requested, a proxy statement, Marinus annual report, and form of proxy card. I present to this meeting the affidavit as to the due mailing of the notice. I will see that this is filed with the minutes of the meeting. A list of stockholders as of the record date is available for review on the Materials section of the annual meeting portal, which you may access by selecting the Materials button on the bottom right of your screen. The stockholder list shows holders of 36,633,490 shares of Marinus common stock are entitled to vote at this meeting. Under Marinus bylaws, the presence of at least one-third of all shares of Marinus common stock outstanding as of the record date, either present by remote communication or represented by proxy, is necessary to constitute a quorum for the transaction of business at the meeting. We are informed by the Inspector of Elections that they are represented by remote communication or proxy 26,860,105 shares of common stock, or approximately 73.32% of all shares outstanding as of the record date. A quorum is therefore present and this annual meeting of stockholders is properly and legally convened for the purpose of transacting business properly before it. Thank you, Martha. The first order of business is a discussion of the matters to be voted on at today's meeting. Voting will commence after all proposals have been presented. First proposal is the election of three Class One directors to Marinus' board of directors, each to serve until the 2024 annual meeting of stockholders or until such person's successor is duly elected and qualified. The Class One directors are Charles Austin, Michael Dougherty, and Alan Isaacson. The board of directors recommends a vote for all of the Class One directors. Marinus has an advance notice provision in its bylaws for director nominations, and we have not received any notice from any of our stockholders of any other matters to be considered at the annual meeting. Accordingly, all nominations are now closed. The second proposal is the ratification of the appointment of Ernst & Young LLP as Marinus' independent registered public accounting firm for the fiscal year ending December 31st, 2021. The board of directors recommends a vote for that ratification. The third and final proposal is the approval on a non-binding advisory basis of the compensation of Marinus' named executive officers as disclosed in the proxy statement. The board of directors recommends a vote for the approval on a non-binding advisory basis of the compensation of Marinus' named executive officers as disclosed in the proxy statement. If you would like to make any remarks concerning any of these proposals, please submit your comments and questions through the website. Because no further business is on the agenda to come before this meeting, we will now move on to voting. Voting will proceed after I declare that the polls are open. If you have previously voted by proxy, whether via email, mail, telephone, fax, or the internet as provided in the proxy statement, your shares will be voted accordingly. Any stockholder who has not yet voted or wish to change their votes may do so by clicking on the voting button on the bottom right of the web portal and following the instructions. Stockholders who have sent in proxies or voted via other methods outlined in the proxy statement and do not want to change their votes do not need to take any further action. Voting will be open during the business portion of the meeting, and the polls will close following consideration of each of the proposals on the agenda. Please note that voting during the meeting will revoke any previously submitted proxy or voting instructions. As a reminder, attending this meeting will not by itself cause your previously submitted proxy or voting instructions to be revoked. I declare the polls now open for each matter to be voted on today. I ask that the Secretary note the time of the opening of the polls in the minutes. Thank you. I now declare the polls closed. I ask that the Secretary note the time of the closing of the polls in the minutes and that the Inspector of Elections tabulate the votes. Ms. Manning, please report the preliminary voting results when ready. The votes have been tabulated. On proposal number 1, having received a plurality of the votes of the holders of the shares of common stock present by remote communication or represented by proxy at this meeting and entitled to vote generally on the election of directors, the three Class I directors have each been elected to serve as members of Marinus' board of directors until the 2024 annual meeting of stockholders or until such person's successor is duly elected and qualified. On proposal 2, having received the affirmative vote of the holders of the majority of the shares of common stock present by remote communication or represented by proxy at this meeting and entitled to vote on this matter, the appointment of Ernst & Young LLP as Marinus' independent registered public accounting firm for the fiscal year ending December 31, 2021, has been ratified. On proposal number 3, having received the affirmative vote of the holders of the majority of the shares of common stock present by remote communication or represented by proxy at this meeting and entitled to vote on this matter, the executive compensation of our named executive officers has been approved on a non-binding advisory basis by the stockholders. I, as the Inspector of Elections, will prepare a written certificate documenting the results of the voting and certain other matters. Thank you, Martha. There being no further business to be transacted at this meeting, the formal meeting adjourned. I ask that the secretary note the time of adjournment of the meeting in the minutes. I would now like to move to the question and answer portion of our meeting. In addition to the members of management and Marinus' board of directors in attendance today, Ryan Carrozza of Ernst & Young LLP is available to respond to questions. You will now have the opportunity to submit questions by selecting the Q&A button on the bottom right of your screen. We will endeavor to answer as many submitted questions as time permits. However, we reserve the right to exclude questions regarding topics that are not pertinent to meeting matters or company business or are inappropriate. If we receive substantially similar questions, we will group such questions together and provide a single response to avoid repetition. Any questions that are appropriate and pertinent to the annual meeting but cannot be answered during the annual meeting due to time constraints will be answered and posted on our investor relations website at www.ir.marinuspharma.com as soon as practical after the annual meeting. There being no further questions, our program has concluded. Thank you all for attending today's meeting and for your continuing support of Marinus Pharmaceuticals.